Vivo Bio Tech Peer Comparison

BSE: 511509

₹14.00

₹-1.02 (-6.79%)

As on 15-Oct-2026 13:44IST

Market cap

₹32 Cr

Revenue (TTM)

₹55 Cr

P/E Ratio

P/B Ratio

0.3

Div. Yield

0 %

Edit

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Market cap (₹ Cr)	32	2,399	303	165	10
Revenue (₹ Cr)	55	2,901	138	85	0
Net Profit (₹ Cr)	-2.86	16.16	-9.39	12.82	0.02
Net Margin (%)	-5.15	0.55	-6.66	6.38	9.72
RoE (%)	-16.06	0.29	-9.20	20.84	0.53
Price to Earnings	--	148.44	--	12.83	498.90
Price-To-Book	0.35	0.36	3.21	5.13	2.66

Income Statement (₹ Cr)

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Operating Revenue	53.33	2,931.90	128.44	54.19	0.84
Total Income	53.78	2,987.84	131.94	60.87	0.85
Total Expenditure	32.43	2,366.27	131.93	56.10	0.40
EBITDA	20.91	565.63	-3.49	-1.91	0.44
Depreciation	10.63	338.69	8.46	0.01	0.00
EBIT	10.28	226.94	-11.95	-1.92	0.44
Interest	5.91	174.18	3.33	0.35	0.00
Other Income	0.44	55.94	3.50	6.69	0.00
Exceptional Items	--	-3.80	--	--	--
Profit before Tax	4.81	104.90	-11.78	4.42	0.44
Provision for Tax	6.52	7.45	-1.34	0.16	0.09
Profit after Tax	-1.71	97.45	-10.44	4.26	0.36

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Shareholder's Funds	93.16	6,676.90	92.39	31.00	3.90
Minority Interest	--	--	-1.56	0.00	--
Non-Current Liabilities	55.04	2,846.00	29.81	0.00	0.00
Current Liabilities	30.23	2,317.05	53.90	5.24	0.46
Total Liabilities	178.43	11,911.40	174.54	36.24	4.36

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Non-Current Assets	149.74	8,997.85	111.26	12.48	1.73
Current Assets	28.42	2,842.10	63.28	23.77	2.62
Total Assets	178.43	11,911.40	174.54	36.24	4.36
Total Debt*	67.38	2,775.40	48.36	0.00	0.00
Net Current Assets	-1.82	525.05	9.38	18.53	2.16
Contingent Liabilities	--	428.74	37.44	--	--

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Cash From Operating Activities	34.93	491.45	5.24	-4.13	0.03
Cash Flow from Investing Activities	-59.35	-245.34	-9.41	1.74	0.01
Cash from Financing Activities	24.57	200.58	4.19	-0.72	--
Net Cash Inflow / Outflow	0.15	446.69	0.02	-3.11	0.04

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
ROCE (%)	7.34	3.21	-5.96	18.49	11.87
ROE (%)	-2.11	1.56	-10.64	16.52	9.57
ROA (%)	-1.06	0.89	-5.95	11.71	8.20
EBIT Margin (%)	40.03	21.20	0.01	8.81	52.63
Net Margin (%)	-3.18	3.26	-7.91	6.99	41.97
Cash Profit Margin (%)	16.72	14.88	-1.54	7.87	42.50

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Revenue Growth (%)	14.27	8.13	-7.26	-100.00	411.25
EBIT Growth (%)	-15.82	26.69	-99.94	73.95	2,529.91
Net Profit Growth (%)	-123.46	2,907.72	-231.54	476.63	2,245.51
EPS Growth (%)	-118.15	2,908.18	-225.21	-71.28	2,245.67
Book Value Growth (%)	29.61	14.50	-11.84	51.02	10.05

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Price / Earnings	0.00	20.92	0.00	53.86	50.26
Price / Book Value	0.51	0.31	1.74	18.91	4.59
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	5.28	6.15	0.00	122.77	40.19
Market Cap (₹ Cr)	46.71	2,038.26	159.68	586.26	17.90

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Debt to Equity	0.74	0.42	0.53	0.00	0.00
Short term debt to equity ratio	0.13	0.13	0.21	--	--
Current Ratio	0.94	1.23	1.17	4.54	5.73
Quick Ratio	0.67	0.79	0.92	4.54	5.11
Interest Coverage	1.81	1.60	-2.54	13.66	2,845.31

	Vivo Bio Tech	Dishman Carbogen	Lyka Labs	Take Solutions	Genomic Biotech
Debtors to sales (%)	22.03	22.95	27.28	0.40	262.40
Asset Turnover	0.33	0.27	0.73	1.49	0.19
Receivable days	78.69	83.29	110.99	1.47	1,026.01
Inventory Days	54.55	119.47	37.08	0.00	122.93
Payable days	66.07	197.26	115.42	9.35	554.30
Cash Conversion Cycle	67.17	5.50	32.64	-7.88	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.